Wednesday, November 15, 2023
Print Current Session:
![]() |
|
Wednesday
SESSION 31:
ADVANCES IN MEDICAL TREATMENTS, NEW ANTI-ATHEROGENIC DRUGS, VALUE OF RIVAROXABAN AND PREVENTING MIs IN VASCULAR SURGERY PATIENTS
|
|
SESSION 31 SCHEDULE | |
6:40 AM - 6:45 AM | When, Why And How To Lower High Triglyceride Levels: Value Of Vascepa To Decrease Cardiac Risk In Vascular Patients: Based On The REDUCE-IT RCT |
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC Location: Grand Ballroom West, 3rd Floor |
|
6:46 AM - 6:51 AM | New Strategies On How To Avoid And Treat Periprocedural Myocardial Infarctions (MIs) In Open Endo Vascular Surgery Patients |
Presenter(s):Peter Henke, MD Location: Grand Ballroom West, 3rd Floor |
|
6:52 AM - 6:57 AM | DEBATE: LDL Cholesterol (LDL-C) Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful: What Does The Latest Evidence Show |
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC PhD FACS Location: Grand Ballroom West, 3rd Floor |
|
6:58 AM - 7:03 AM | DEBATE: Not So: Update On LDL-C Lowering With Statins And Other Drugs Stabilizes And Shrinks Plaques And Decreases Morbid Vascular Events: Stopping Statins Increases Patients’ Risk Of MI And Death |
Presenter(s):Ron Waksman, MD Location: Grand Ballroom West, 3rd Floor |
|
7:04 AM - 7:09 AM | Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured |
Presenter(s):J. David Spence, MD Location: Grand Ballroom West, 3rd Floor |
|
7:10 AM - 7:15 AM | LDL-C Lowering Should Be Maximized With High Dose Statins And Ezetimibe (Zetia) To Minimize Risks From Atherosclerotic Lesions: The LDL-C Level Cannot Be Too Low And Side Effects Are Minor: LDL-C Levels Must Be Monitored And Treated To A Target Level |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP Location: Grand Ballroom West, 3rd Floor |
|
7:16 AM - 7:21 AM | New Findings From The VOYAGER PAD And COMPASS Trials With Low Dose Rivaroxaban (Xarelto From Janssen And J&J) And Aspirin: How Do These Drugs Lower Major Adverse Limb And Cardiac Event Rates After Lower Extremity Revascularization (Endo And Open) For PAD |
Presenter(s):Marianne Brodmann, MD / Sebastian E. Debus, MD, PhD Location: Grand Ballroom West, 3rd Floor |
|
7:22 AM - 7:27 AM | How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC Location: Grand Ballroom West, 3rd Floor |
|
7:28 AM - 7:33 AM | New Adjunctive Drugs (Plus Statins) To Lower LDL-Cholesterol (LDL-C) In Vascular Patients: Inclisiran, Bempedoic Acid And Ezetimibe: How Do They Work And When And How To Use Them: Level Of LDL-C To Strive For: The CLEAR RCT Show That Bempedoic Acid Really Works |
Presenter(s):Richard Bulbulia, MA, MD, FRCS Location: Grand Ballroom West, 3rd Floor |
|
7:34 AM - 7:42 AM | Panel Discussion |
END OF SESSION 31 | |
previous | next |